Russell Investments Group Ltd. reduced its position in shares of Mednax, Inc (NYSE:MD) by 33.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 44,400 shares of the company’s stock after selling 22,141 shares during the period. Russell Investments Group Ltd.’s holdings in Mednax were worth $2,682,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Pacer Advisors Inc. boosted its stake in shares of Mednax by 3.2% in the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock worth $125,000 after buying an additional 55 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Mednax by 870.9% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 2,000 shares of the company’s stock worth $139,000 after buying an additional 1,794 shares during the last quarter. Morgan Dempsey Capital Management LLC boosted its stake in shares of Mednax by 3.6% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,270 shares of the company’s stock worth $157,000 after buying an additional 78 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in shares of Mednax by 4.4% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,428 shares of the company’s stock worth $158,000 after buying an additional 102 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in shares of Mednax by 8.7% in the first quarter. Daiwa Securities Group Inc. now owns 2,500 shares of the company’s stock worth $173,000 after buying an additional 200 shares during the last quarter.

Mednax, Inc (NYSE:MD) traded down 1.58% during midday trading on Friday, reaching $44.14. 324,017 shares of the company traded hands. The firm has a market capitalization of $4.07 billion, a price-to-earnings ratio of 14.06 and a beta of 0.40. Mednax, Inc has a one year low of $41.52 and a one year high of $72.13. The firm has a 50-day moving average price of $48.00 and a 200-day moving average price of $58.95.

Mednax (NYSE:MD) last posted its earnings results on Friday, July 28th. The company reported $0.85 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.04. The business had revenue of $843 million during the quarter, compared to analyst estimates of $849.49 million. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The company’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.03 EPS. Equities analysts predict that Mednax, Inc will post $3.31 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/09/01/russell-investments-group-ltd-sells-22141-shares-of-mednax-inc-md.html.

A number of brokerages have recently issued reports on MD. Stephens raised shares of Mednax from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $55.00 to $68.00 in a research report on Thursday, June 22nd. Stifel Nicolaus reduced their target price on shares of Mednax from $65.00 to $58.00 and set a “hold” rating for the company in a research report on Thursday, May 25th. Mizuho reduced their target price on shares of Mednax from $64.00 to $58.00 and set a “neutral” rating for the company in a research report on Tuesday, May 30th. BidaskClub raised shares of Mednax from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 13th. Finally, Jefferies Group LLC set a $46.00 target price on shares of Mednax and gave the company a “hold” rating in a research report on Sunday, July 30th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and one has assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $63.00.

In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,969 shares of Mednax stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total transaction of $113,355.33. Following the completion of the transaction, the director now owns 18,072 shares of the company’s stock, valued at approximately $1,040,405.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.40% of the stock is owned by insiders.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.